Ascendis制药 ASND 深 沪
等待开盘 11-05 09:30:00 美东时间
206.04
+5.060
+2.52%
华盛通- 最 高206.42
- 今 开200.98
- 成交量 19.48万股
- 最 低 197.60
- 昨 收 200.98
- 总市值 124.77亿
- 52周最高 216.45
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 118.03
- 委 比 27.84%
- 总股本 6055.44万
- 历史最高 216.45
- 量 比 0.72
- 振 幅 4.39%
- 历史最低 11.92
- 每 手 1
- 风险率 26.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ascendis Pharma To Present Three-Year Data From Its Phase 2 And 3 Trials Showing Sustained Renal Function Improvement, Normalized Urine Calcium, And Continued Safety And Efficacy Of TransCon PTH In Adults With Hypoparathyroidism At The American Society For Nephrology's Kidney Week 2025
Ascendis Pharma A/S (NASDAQ:ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium handling, and continued safety and efficacy in adults with
11-04 05:04
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
Raymond James Initiates Coverage On Ascendis Pharma with Strong Buy Rating, Announces Price Target of $271
Raymond James analyst Martin Auster initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Strong Buy rating and announces Price Target of $271.
10-17 23:32
Ascendis Pharma Grants Employee Warrants to Boost Engagement
Ascendis Pharma ( ($ASND) ) has shared an announcement. On October 14, 2025, As...
10-16 04:56
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
Ascendis Pharma Submits Marketing Authorisation Application To The European Medicines Agency For TransCon CNP As A Treatment For Children With Achondroplasia
COPENHAGEN, Denmark, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon
10-09 04:03
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia
Ascendis Pharma has submitted a Marketing Authorisation Application (MAA) to the EMA for TransCon CNP, a weekly-administered drug aimed at treating children with achondroplasia. The application is supported by data from clinical trials and open-label extensions, showing the drug is generally well-tolerated. TransCon CNP works by continuously inhibiting the overactive FGFR3 pathway, addressing a rare genetic disorder affecting bone growth and caus...
10-08 20:01
Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
An announcement from Ascendis Pharma ( ($ASND) ) is now available. On September...
10-01 04:39
What Does the Market Think About Ascendis Pharma AS?
Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has fallen 14.63% since its last report. According to exchange reported data, there are now 2.29 million shares sold short, which is 4.55% of all regular shares that are available for trading.
09-30 01:00
